Advertisement

Advertisement

ZLDAF Stock Latest News

Zelira Secures Director Loan on Premium-Priced Convertible Terms

Company AnnouncementsZelira Secures Director Loan on Premium-Priced Convertible Terms

Zelira Raises US$33m for HOPE® 1 SPV to Accelerate FDA Pathway

PremiumCompany Announcements

Zelira Raises US$33m for HOPE® 1 SPV to Accelerate FDA Pathway

2M ago

Zelira Secures US$33m Strategic Investment to Advance HOPE® 1 Autism Therapy

PremiumCompany Announcements

Zelira Secures US$33m Strategic Investment to Advance HOPE® 1 Autism Therapy

3M ago

Zelira Therapeutics Adjusts Director’s Interest with Convertible Notes

PremiumCompany Announcements

Zelira Therapeutics Adjusts Director’s Interest with Convertible Notes

4M ago

Zelira Therapeutics Issues Unquoted Convertible Notes

PremiumCompany Announcements

Zelira Therapeutics Issues Unquoted Convertible Notes

4M ago

Zelira Therapeutics Secures $1.07 Million R&D Tax Refund

PremiumCompany AnnouncementsZelira Therapeutics Secures $1.07 Million R&D Tax Refund

5M ago

Zelira Therapeutics Announces Proposed Securities Issue

Company Announcements

Zelira Therapeutics Announces Proposed Securities Issue

5M ago

Zelira Therapeutics Focuses on Operational Scale in 2025

Company Announcements

Zelira Therapeutics Focuses on Operational Scale in 2025

5M ago

Zelira Therapeutics Secures R&D Loan and Advances Clinical Trials

PremiumCompany Announcements

Zelira Therapeutics Secures R&D Loan and Advances Clinical Trials

6M ago

Zelira Therapeutics Announces Cessation of Securities

PremiumCompany Announcements

Zelira Therapeutics Announces Cessation of Securities

6M ago

Zelira Therapeutics Announces Key Resolutions for Upcoming AGM

PremiumCompany Announcements

Zelira Therapeutics Announces Key Resolutions for Upcoming AGM

6M ago

Zelira Therapeutics Releases 2025 Corporate Governance Statement

PremiumCompany Announcements

Zelira Therapeutics Releases 2025 Corporate Governance Statement

7M ago

Zelira Therapeutics Secures Director Loans to Enhance Working Capital

PremiumCompany AnnouncementsZelira Therapeutics Secures Director Loans to Enhance Working Capital

7M ago

Zelira Therapeutics Reports Increased Loss Amidst Clinical Progress and Expansion Plans

Company Announcements

Zelira Therapeutics Reports Increased Loss Amidst Clinical Progress and Expansion Plans

8M ago

Zelira Therapeutics Advances Diabetic Neuropathy Study and Strengthens Financial Position

Company Announcements

Zelira Therapeutics Advances Diabetic Neuropathy Study and Strengthens Financial Position

9M ago

Zelira Therapeutics Secures $650,000 R&D Loan Facility to Advance Clinical Trials

PremiumCompany Announcements

Zelira Therapeutics Secures $650,000 R&D Loan Facility to Advance Clinical Trials

9M ago

Zelira Therapeutics’ ZLT-L-007 Shows Promising Results in Diabetic Neuropathy Study

PremiumCompany Announcements

Zelira Therapeutics’ ZLT-L-007 Shows Promising Results in Diabetic Neuropathy Study

11M ago

Zelira Therapeutics Strengthens Financial Position and Advances Product Development

PremiumCompany Announcements

Zelira Therapeutics Strengthens Financial Position and Advances Product Development

12M ago

Zelira Therapeutics Converts $3.25M Notes to Equity, Advances Autism Treatment Trials

PremiumCompany Announcements

Zelira Therapeutics Converts $3.25M Notes to Equity, Advances Autism Treatment Trials

12M ago

Zelira Therapeutics Unveils Strategic Investor Deck

PremiumCompany AnnouncementsZelira Therapeutics Unveils Strategic Investor Deck

1y ago

Zelira Therapeutics Expands Market Presence with New Securities Quotation

Company Announcements

Zelira Therapeutics Expands Market Presence with New Securities Quotation

1y ago

Zelira Therapeutics Launches Share Offer to Raise Capital

Company Announcements

Zelira Therapeutics Launches Share Offer to Raise Capital

1y ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >